Actemra: anaphylaxis riskHoffmann-La Roche and Health Canada warn about potential risk of fatal anaphylaxis with Actemra (tocilizumab). Arthritis care benefits from team approachLeading Ontario clinic spreading its model of chronic disease management across Canada Rheumatoid arthritis redefined Canadian doctor played a major role in international effort to overhaul RA criteria Cherries aid gout treatment Consider concentrated juice as an adjunct to urate-lowering therapy, researcher says Drinking decreases arthritis risk Study links alcohol consumption with reduced likelihood of several inflammatory conditions New drugs on the way for gout Experimental compounds control pain and reduce serum uric acid levels Tech refresher: Helping patients get a grip on arthritis First IL-6 receptor inhibitor for rheumatoid arthritis Hoffmann-La Roche will soon be introducing Actemra (tocilizumab), the first interleukin-6 (IL-6) receptor inhibitor to be approved for the treatment of rheumatoid arthritis (RA). Popular assessment tool a poor predictor of cardiovascular risk in rheumatoid arthritis patients Rheumatoid arthritis care remains suboptimal Canadian study suggests early, aggressive treatment has not caught on in primary care, especially DMARDs First Previous 18 19 20 Next Last
